Cargando…
Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway
Liraglutide, as a glucagon-like peptide-1 analogue, is used to treat type 2 diabetes mellitus and obesity. Previous findings have demonstrated the effects of liraglutide on adipogenesis; however, the underlying mechanism involved in this process remains to be elucidated. In the present study, to cer...
Autores principales: | Li, Yongmei, Du, Jianying, Zhu, Endong, Zhang, Juanjuan, Han, Jie, Zhao, Wei, Sun, Bei, Tian, Derun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802226/ https://www.ncbi.nlm.nih.gov/pubmed/29344656 http://dx.doi.org/10.3892/mmr.2018.8438 |
Ejemplares similares
-
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro
por: Zhu, Endong, et al.
Publicado: (2016) -
YAP promotes osteogenesis and suppresses adipogenic differentiation by regulating β-catenin signaling
por: Pan, Jin-Xiu, et al.
Publicado: (2018) -
Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance
por: Wang, Dong-Yu, et al.
Publicado: (2016) -
YAP and the Hippo pathway in cholangiocarcinoma
por: Sugihara, Takaaki, et al.
Publicado: (2019) -
Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
por: Fan, Mengyang, et al.
Publicado: (2022)